Poiesis and Praxis 4 (2):129-143 (2006)
|Abstract||Parkinsonâs disease (PD) is a common neurodegenerative disorder of the nervous system that affects about 1 in 800 people and for which we have symptomatic but not curative therapies. At the core of the disease is the loss of a specific population of dopaminergic neurons within the brain, and replacement of dopamine through drug therapies has provided clinically significant benefit for many patients. However this therapy only ever offers a temporary amelioration of symptoms and with time this symptomatic therapy becomes less efficacious and produces its own unique side-effects. As a result more effective curative therapies have been sought, including the use of cell based therapies to replace the lost dopaminergic neurons. In this review I am going to discuss PD and its possible repair using neural transplants. In particular I am going to discuss which type of cells are best considered as a reparative therapy, where they should be transplanted in the brain, when in the disease course and in which type of patient. By considering these issues, I hope to be able to make some recommendations as to the future use of this approach in PD|
|Keywords||No keywords specified (fix it)|
No categories specified
(categorize this paper)
|Through your library||Configure|
Similar books and articles
S. Matthew Liao, P. J. Goldschmidt & J. Sugarman (2007). Ethical and Policy Issues Relating to Progenitor-Cell-Based Strategies for Prevention of Atherosclerosis. Journal of Medical Ethics 33 (11):643-646.
Teresa Swift & Richard Huxtable (2013). The Ethics of Sham Surgery in Parkinson's Disease: Back to the Future? Bioethics 27 (4):175-185.
Niklas Mattsson, David Brax & Henrik Zetterberg (2010). To Know or Not to Know - Ethical Issues Related to Early Diagnosis of Alzheimer's Disease. International Journal of Alzheimer's Disease.
Raúl de la Fuente-Fernández & A. Jon Stoessl (2004). The Biochemical Bases of the Placebo Effect. Science and Engineering Ethics 10 (1).
Bernhard Bogerts (2002). Does Catatonia Have a Specific Brain Biology? Behavioral and Brain Sciences 25 (5):580-581.
Georg Northoff (2002). What Catatonia Can Tell Us About “Top-Down Modulation”: A Neuropsychiatric Hypothesis. Behavioral and Brain Sciences 25 (5):555-577.
Matthew A. Lambon Ralph & Peter Garrard (2001). Category-Specific Deficits: Insights From Semantic Dementia and Alzheimer's Disease. Behavioral and Brain Sciences 24 (3):485-486.
Irwin Savodnik (2002). The Disease Status of Catatonia. Behavioral and Brain Sciences 25 (5):590-591.
Ronald K. F. Fung & Ian H. Kerridge (2013). Uncertain Translation, Uncertain Benefit and Uncertain Risk: Ethical Challenges Facing First-in-Human Trials of Induced Pluripotent Stem (Ips) Cells. Bioethics 27 (2):89-96.
Benjamin Seltzer, Jennifer J. Vasterling, Charles W. Mathias & Angela Brennan (2001). Clinical and Neuropsychological Correlates of Impaired Awareness of Deficits in Alzheimer Disease and Parkinson Disease: A Comparative Study. Neuropsychiatry, Neuropsychology, and Behavioral Neurology 14 (2):122-129.
Conrado Bosman, Enzo Brunetti & Francisco Aboitiz (2004). Schizophrenia is a Disease of General Connectivity More Than a Specifically “Social Brain” Network. Behavioral and Brain Sciences 27 (6):856-856.
Piero Antuono & Jan Beyer (1999). The Burden of Dementia: A Medical and Research Perspective. Theoretical Medicine and Bioethics 20 (1):3-13.
Sorry, there are not enough data points to plot this chart.
Added to index2010-09-02
Total downloads1 ( #291,125 of 722,745 )
Recent downloads (6 months)0
How can I increase my downloads?